Skip to main navigation
Skip to content
Skip to content
PDL Logo Blue Green
  • About PDL
    • Leadership
  • Equity Investments
    • Noden
    • Noden’s Products
    • Lensar
    • LENSAR Product
  • Alternative Financings
    • Portfolio of Assets
    • On-Going Transactions
    • Concluded Transactions
  • Investor Relations
  • News
  • Contact
  • About PDL
    • Management
  • Equity Investments
    • Noden
    • Noden’s Products
    • Lensar
    • LENSAR Product
  • Alternative Financings
    • Portfolio of Assets
    • On-Going Transactions
    • Concluded Transactions
  • Investor Relations
  • News
  • Contact

Press Releases

PDL  > Investor Relations > Press Releases

Press Releases

  • Summary TogglePDL BioPharma Announces Fourth Quarter and Year End 2017 Financial Results
    Total Revenues Increased by 31% in 2017
    GAAP EPS Increased 350% and 82% for Q417 and FY 2017, respectively
    Mar 8, 2018
    PDL BioPharma Announces Fourth Quarter and Year End 2017 Financial Results 60.9 KB
  • Summary TogglePDL BioPharma to Announce Fourth Quarter / Year-End 2017 Financial Results on March 8, 2018
    INCLINE VILLAGE, Nev. , March 1, 2018 /PRNewswire/ --  PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter, year-end 2017 financial results for the period ended December 31, 2017 , on Thursday March 8, 2018 , after market close.
    Mar 1, 2018
    PDL BioPharma to Announce Fourth Quarter / Year-End 2017 Financial Results on March 8, 2018 23.2 KB
  • Summary TogglePDL BioPharma Terminates Interest in Pursuing Acquisition of Neos
    -- PDL does not plan to make any further proposals to acquire Neos --
    Feb 20, 2018
    PDL BioPharma Terminates Interest in Pursuing Acquisition of Neos 23.1 KB
  • Summary TogglePDL BioPharma to Present at Two Upcoming Investor Conferences
    INCLINE VILLAGE, Nev. , Feb. 14, 2018 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's chief executive officer, will present at the following two upcoming investor conferences: 2018 RBC Capital Markets Global Healthcare Conference Wednesday
    Feb 14, 2018
    PDL BioPharma to Present at Two Upcoming Investor Conferences 22.5 KB
  • Summary TogglePDL BioPharma's Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale Process
    INCLINE VILLAGE, Nev. , Nov. 8, 2017 /PRNewswire/ --  PDL BioPharma, Inc. (NASDAQ: PDLI) reiterated that its proposal to acquire Neos Therapeutics, Inc. (NASDAQ: NEOS) for $10.25 per share in cash will expire today at market close. PDL originally made public its proposal to acquire Neos on October
    Nov 8, 2017
    PDL BioPharma's Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale Process 26.6 KB
  • Summary TogglePDL BioPharma to Present at Two Upcoming Investor Conferences
    INCLINE VILLAGE, Nev. , Nov. 7, 2017 /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's president and chief executive officer, will present at two investor conferences in November. Jefferies 2017 London Healthcare Conference Wednesday,
    Nov 7, 2017
    PDL BioPharma to Present at Two Upcoming Investor Conferences 22.2 KB
  • Summary TogglePDL BioPharma Announces Third Quarter 2017 Financial Results
    Third Quarter GAAP EPS Increased 75%
    Total Revenues Increased by 17% and 42% for 3Q17 and YTD 2017, respectively
    Nov 2, 2017
    PDL BioPharma Announces Third Quarter 2017 Financial Results 64.2 KB
  • Summary TogglePDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition Proposal
    INCLINE VILLAGE, Nev. , Oct. 30, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today issued the following statement in response to the Neos Therapeutics, Inc. ("Neos") (NASDAQ: NEOS) Board of Directors' rejection of PDL's October 26 proposal to acquire Neos for
    Oct 30, 2017
    PDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition Proposal 23 KB
  • Summary TogglePDL BioPharma Announces Settlement Agreement with Valeant
    INCLINE VILLAGE, Nevada , Oct. 30, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) today announced that on October 27, 2017 , PDL and Depomed, Inc. ("Depomed") entered into a settlement agreement with Valeant Pharmaceuticals International, Inc.
    Oct 30, 2017
    PDL BioPharma Announces Settlement Agreement with Valeant 23 KB
  • Summary TogglePDL BioPharma Proposes to Acquire Neos Therapeutics for $10.25 per Share in Cash
    - Proposal provides immediate and certain value to Neos shareholders
    - Proposal represents a 40% premium to Neos' October 25 closing price and provides shareholders a substantial premium
    - Supports PDL's specialty pharmaceutical acquisition strategy
    Oct 26, 2017
    PDL BioPharma Proposes to Acquire Neos Therapeutics for $10.25 per Share in Cash 28.4 KB
  • Summary TogglePDL BioPharma to Announce Third Quarter 2017 Financial Results on November 2, 2017
    INCLINE VILLAGE, Nev. , Oct. 25, 2017 /PRNewswire/ --  PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its third quarter financial results for the period ended September 30, 2017 , on Thursday, November 2, 2017 , after market close.
    Oct 25, 2017
    PDL BioPharma to Announce Third Quarter 2017 Financial Results on November 2, 2017 22.5 KB
  • Summary TogglePDL BioPharma Announces New $25 Million Share Repurchase Program
    INCLINE VILLAGE, Nev. , Sept. 25, 2017 /PRNewswire/ --  PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) announced today that PDL's board of directors has authorized a new stock repurchase program to acquire up to $25 million of the Company's common stock.  Purchases may be made in
    Sep 25, 2017
    PDL BioPharma Announces New $25 Million Share Repurchase Program 23.4 KB
  • Summary TogglePDL BioPharma Updates Presentation Time for Cantor Fitzgerald Conference
    INCLINE VILLAGE, Nev. , Sept. 19, 2017 /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's chief executive officer, will present at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York City on Tuesday, September 26, 2017 , at
    Sep 19, 2017
    PDL BioPharma Updates Presentation Time for Cantor Fitzgerald Conference 21.5 KB
  • Summary TogglePDL BioPharma Appoints Dominique Monnet as President
    INCLINE VILLAGE, Nev. , Sept. 11, 2017 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company has appointed Dominique P. Monnet to the position of president. Mr. Monnet brings over 30 years of international business experience in the biotechnology /
    Sep 11, 2017
    PDL BioPharma Appoints Dominique Monnet as President 25.6 KB
  • Summary TogglePDL BioPharma to Present at Two Upcoming Investor Conferences
    INCLINE VILLAGE, Nev. , Sept. 6, 2017 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's president and chief executive officer, will present at two investor conferences in September. Rodman & Renshaw 19 th Annual Global Investment Conference
    Sep 6, 2017
    PDL BioPharma to Present at Two Upcoming Investor Conferences 22 KB

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • …
  • Next page Next
  • Last page Last

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Tax Information
    • SEC Filings
    • Stock Information
    • Contact Us

    Current Alternative Investments

    image

    Learn More

     

    Shareholder Tools

    • Printed Materials
    • Email Alerts
    • RSS
    • Print
    • Share
    • Search
    • Facebook
    • Google
    • LinkedIn
    • Twitter
    • RSS

PDL Logo White Fill

  • Terms of Use
  • Sitemap
© Copyright 2019 PDL BioPHARMA. All Rights Reserved.